Lisdexamfetamine dimesylate: the first long-acting prodrug stimulant treatment for attention deficit/hyperactivity disorder (Q57400056)

From Wikidata

Jump to navigation Jump to search

article by Stephen Faraone published June 2008 in Expert Opinion on Pharmacotherapy

Language	Label	Description	Also known as
English	Lisdexamfetamine dimesylate: the first long-acting prodrug stimulant treatment for attention deficit/hyperactivity disorder	article by Stephen Faraone published June 2008 in Expert Opinion on Pharmacotherapy

Statements

scholarly article

0 references

Lisdexamfetamine dimesylate: the first long-acting prodrug stimulant treatment for attention deficit/hyperactivity disorder (English)

0 references

attention deficit hyperactivity disorder

0 references

1 reference

based on heuristic

inferred from title

Stephen Faraone

object named as

Stephen V Faraone

1

0 references

language of work or name

0 references

publication date

June 2008

0 references

Expert Opinion on Pharmacotherapy

0 references

9

0 references

9

0 references

1565-1574

0 references

Attention deficit hyperactivity disorder: guidelines for investigating efficacy of pharmacological intervention

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.9.1565

21 January 2018

Attention-deficit hyperactivity disorder

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.9.1565

21 January 2018

What is the prevalence of adult ADHD? Results of a population screen of 966 adults

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.9.1565

21 January 2018

The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.9.1565

21 January 2018

Clinical and diagnostic implications of lifetime attention-deficit/hyperactivity disorder comorbidity in adults with bipolar disorder: data from the first 1000 STEP-BD participants

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.9.1565

21 January 2018

The neuropsychopharmacology of attention-deficit/hyperactivity disorder

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.9.1565

21 January 2018

Neuropsychopharmacological mechanisms of stimulant drug action in attention-deficit hyperactivity disorder: a review and integration.

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.9.1565

21 January 2018

New formulations of stimulants for attention-deficit hyperactivity disorder: therapeutic potential

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.9.1565

21 January 2018

Clinical practice guideline: treatment of the school-aged child with attention-deficit/hyperactivity disorder

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.9.1565

21 January 2018

History and current perspectives on the use of drug formulations to decrease the abuse of prescription drugs

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.9.1565

21 January 2018

Variables That Affect the Clinical Use and Abuse of Methylphenidate in the Treatment of ADHD

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.9.1565

21 January 2018

PET study examining pharmacokinetics, detection and likeability, and dopamine transporter receptor occupancy of short- and long-acting oral methylphenidate

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.9.1565

21 January 2018

Pharmacokinetics of SLI381 (ADDERALL XR), an extended-release formulation of Adderall

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.9.1565

21 January 2018

Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.9.1565

21 January 2018

Development of a new once-a-day formulation of methylphenidate for the treatment of attention-deficit/hyperactivity disorder: proof-of-concept and proof-of-product studies

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.9.1565

21 January 2018

Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit/hyperactivity disorder: a phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study.

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.9.1565

21 January 2018

Lisdexamfetamine

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.9.1565

21 January 2018

Relative bioavailability of lisdexamfetamine 70-mg capsules in fasted and fed healthy adult volunteers and in solution: a single-dose, crossover pharmacokinetic study

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.9.1565

21 January 2018

A randomized, double-blind, placebo-controlled, laboratory classroom assessment of methylphenidate transdermal system in children with ADHD.

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.9.1565

21 January 2018

Long-Term Effects of Methylphenidate Transdermal Delivery System Treatment of ADHD on Growth

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.9.1565

21 January 2018

Identifiers

10.1517/14656566.9.9.1565

0 references

PubMed publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q57400056&oldid=1554411756"